<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151901</url>
  </required_header>
  <id_info>
    <org_study_id>19-0045</org_study_id>
    <nct_id>NCT04151901</nct_id>
  </id_info>
  <brief_title>Sex-specific Determinants of Early-phase Recovery From Skeletal Muscle Disuse</brief_title>
  <acronym>MAC</acronym>
  <official_title>Sex-specific Determinants of Early-phase Recovery From Skeletal Muscle Disuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a 2-phase, randomized clinical trial that includes 7 days of unilateral leg&#xD;
      disuse (Phase 1), immediately followed by 14 days of bilateral leg rehabilitation (Phase 2).&#xD;
      The investigators will recruit cohorts of healthy middle-aged men and women to address their&#xD;
      aims:&#xD;
&#xD;
        -  Demonstrate the sex-specific effects of skeletal muscle disuse (Phase 1)&#xD;
&#xD;
        -  Identify key molecular determinates of susceptibility of skeletal muscle atrophy (Phase&#xD;
           1)&#xD;
&#xD;
        -  Map the early, sex-specific molecular time-course of rehabilitation (Phase 2)&#xD;
&#xD;
        -  Determine if disused and healthy muscle respond similarly to exercise (Phase 2)&#xD;
&#xD;
      Healthy, middle-age men and post-menopausal women (50-65 years) will be recruited from the&#xD;
      greater Houston/Galveston area. This under-represented research demographic demonstrate few&#xD;
      negative metabolic or phenotypic signs of advanced age, but are at increased risk of being&#xD;
      hospitalized and experiencing accelerated loss of lean mass and muscle function that&#xD;
      parallels a much older population.&#xD;
&#xD;
      The goal of this study is to characterize phenotypic and molecular skeletal muscle changes in&#xD;
      middle-aged men and women during critical periods of disuse and rehabilitation and ultimately&#xD;
      direct the development of targeted and effective prevention and treatment strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The negative health consequences of muscular disuse in aging populations are unequivocal.&#xD;
      While descriptive, outcome data on disuse and recovery are abundant, key knowledge gaps limit&#xD;
      researcher's ability to implement evidence-based, rehabilitation strategies. Limiters&#xD;
      include: i) an inability to identify individuals most susceptible to disuse, ii) insufficient&#xD;
      information to differentiate between, and respond to, disuse atrophy in men and women, iii)&#xD;
      limited insight into the mechanisms driving adaptation to early rehabilitative exercise, and&#xD;
      iv) the assumption that disused and healthy skeletal muscle will have a similar, positive&#xD;
      response to resistance exercise. The investigators will complete a 2-phase, randomized&#xD;
      clinical trial at the University of Texas Medical Branch (UTMB). The protocol includes 7-days&#xD;
      of unilateral leg disuse (ULD; Phase 1), immediately followed by 14-days of bilateral leg&#xD;
      rehabilitation (Phase 2). Healthy, middle-aged men (n=40) and (post-menopausal) women (n=40),&#xD;
      (50-65 y) will be recruited; a neglected research demographic who present with a largely&#xD;
      youthful phenotype, but are at risk of accelerated disuse atrophy.&#xD;
&#xD;
      This project will provide a highly powered, detailed phenotypic characterization of the&#xD;
      continuum of adults most and least susceptible to muscular disuse. Clinical outcomes will be&#xD;
      supported by RNA deep sequencing and pathway analysis to establish a platform that: i)&#xD;
      improves scientists' ability to identify higher-risk individuals and ii) provides insight&#xD;
      into time-sensitive, sex-specific and effective rehabilitation strategies. Findings and&#xD;
      reposed molecular data from this study, may help identify future therapeutic targets and&#xD;
      serve as an uncomplicated/comorbidity-free baseline for clinical trials in populations&#xD;
      experiencing disuse atrophy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative RNA-sequencing</measure>
    <time_frame>Study day 1 (before starting leg disuse)</time_frame>
    <description>RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative RNA-sequencing</measure>
    <time_frame>Study day 7 (after finishing leg disuse)</time_frame>
    <description>RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative RNA-sequencing</measure>
    <time_frame>Study day 7 (after 1 bout of rehabilitation)</time_frame>
    <description>RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative RNA-sequencing</measure>
    <time_frame>Study day 9 (after 2 bouts of rehabilitation)</time_frame>
    <description>RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative RNA-sequencing</measure>
    <time_frame>Study Day 11 (after 3 bouts of rehabilitation)</time_frame>
    <description>RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative RNA-sequencing</measure>
    <time_frame>Study Day 21 (after finishing 7 bouts of rehabilitation)</time_frame>
    <description>RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle function</measure>
    <time_frame>Study day 1 (before starting leg disuse)</time_frame>
    <description>Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle function</measure>
    <time_frame>Study day 7 (after 1 bout of rehabilitation)</time_frame>
    <description>Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle function</measure>
    <time_frame>Study day 9 (after 2 bouts of rehabilitation)</time_frame>
    <description>Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle function</measure>
    <time_frame>Study Day 11 (after 3 bouts of rehabilitation)</time_frame>
    <description>Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle function</measure>
    <time_frame>Study Day 21 (after finishing 7 bouts of rehabilitation)</time_frame>
    <description>Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body (leg) composition</measure>
    <time_frame>Study day 1 (before starting leg disuse)</time_frame>
    <description>Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body (leg) composition</measure>
    <time_frame>Study day 7 (after finishing leg disuse)</time_frame>
    <description>Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body (leg) composition</measure>
    <time_frame>Study day 9 (after 2 bouts of rehabilitation)</time_frame>
    <description>Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body (leg) composition</measure>
    <time_frame>Study Day 11 (after 3 bouts of rehabilitation)</time_frame>
    <description>Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body (leg) composition</measure>
    <time_frame>Study Day 21 (after finishing 7 bouts of rehabilitation)</time_frame>
    <description>Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber cross sectional area</measure>
    <time_frame>Study day 1 (before starting leg disuse)</time_frame>
    <description>Muscle biopsy samples will be evaluated for muscle fiber cross sectional area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber cross sectional area</measure>
    <time_frame>Study day 7 (after finishing leg disuse)</time_frame>
    <description>Muscle biopsy samples will be evaluated for muscle fiber cross sectional area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber cross sectional area</measure>
    <time_frame>Study day 9 (after 2 bouts of rehabilitation)</time_frame>
    <description>Muscle biopsy samples will be evaluated for muscle fiber cross sectional area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber cross sectional area</measure>
    <time_frame>Study Day 11 (after 3 bouts of rehabilitation)</time_frame>
    <description>Muscle biopsy samples will be evaluated for muscle fiber cross sectional area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber cross sectional area</measure>
    <time_frame>Study Day 21 (after finishing 7 bouts of rehabilitation)</time_frame>
    <description>Muscle biopsy samples will be evaluated for muscle fiber cross sectional area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber type</measure>
    <time_frame>Study day 1 (before starting leg disuse)</time_frame>
    <description>Muscle biopsy samples will be evaluated for muscle fiber type distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber type</measure>
    <time_frame>Study day 7 (after finishing leg disuse)</time_frame>
    <description>Muscle biopsy samples will be evaluated for muscle fiber type distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber type</measure>
    <time_frame>Study day 9 (after 2 bouts of rehabilitation)</time_frame>
    <description>Muscle biopsy samples will be evaluated for muscle fiber type distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber type</measure>
    <time_frame>Study Day 11 (after 3 bouts of rehabilitation)</time_frame>
    <description>Muscle biopsy samples will be evaluated for muscle fiber type distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber type</measure>
    <time_frame>Study Day 21 (after finishing 7 bouts of rehabilitation)</time_frame>
    <description>Muscle biopsy samples will be evaluated for muscle fiber type distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diet recall</measure>
    <time_frame>Familiarization session (~1 week before starting leg disuse)</time_frame>
    <description>A multi-pass 24-hour dietary recall using the Automated Self Assessment 24-h dietary assessment tool to determine habitual food intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diet recall</measure>
    <time_frame>Study day 11 (after two bouts of rehabilitation)</time_frame>
    <description>A multi-pass 24-hour dietary recall using the Automated Self Assessment 24-h dietary assessment tool to determine habitual food intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Study Days -7 to Day 0 (1 week prior to starting leg disuse)</time_frame>
    <description>Accelerometers will placed on the waist and ankle to measure physical activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Study Days 1-6 (1 week of disuse)</time_frame>
    <description>Accelerometers will placed on the waist and ankle to measure physical activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Study Days 7-21 (2 weeks of rehabilitation)</time_frame>
    <description>Accelerometers will placed on the waist and ankle to measure physical activity</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Atrophy of Muscle Due to Disuse</condition>
  <condition>Rehabilitation</condition>
  <arm_group>
    <arm_group_label>Male Rehabilitation (M-REHAB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Disuse + resistance exercise rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male Control (M-CON)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Disuse + ambulatory control rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female Rehabilitation (F-REHAB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Disuse + resistance exercise rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female Control (F-CON)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Disuse + ambulatory control rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resistance Exercise Rehabilitation</intervention_name>
    <description>Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.</description>
    <arm_group_label>Female Rehabilitation (F-REHAB)</arm_group_label>
    <arm_group_label>Male Rehabilitation (M-REHAB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Walking-based rehabilitation</intervention_name>
    <description>Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.</description>
    <arm_group_label>Female Control (F-CON)</arm_group_label>
    <arm_group_label>Male Control (M-CON)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All races and ethnic backgrounds&#xD;
&#xD;
          2. Men and women, age 50-65 years&#xD;
&#xD;
          3. Generally healthy (see exclusion criteria)&#xD;
&#xD;
          4. Able and willing to provide informed consent&#xD;
&#xD;
          5. Ability to speak and read English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Compromised musculoskeletal function that precludes safe participation or use of&#xD;
             crutches&#xD;
&#xD;
          2. Pre-menopausal women&#xD;
&#xD;
          3. Hypogonadal men (testosterone &lt;300 ng/dL)&#xD;
&#xD;
          4. Women taking hormone replacement therapy (HRT)&#xD;
&#xD;
          5. Sarcopenia (European Working Group on Sarcopenia in Older People, EWGSOP102)&#xD;
&#xD;
          6. Clinically significant heart disease (e.g. New York Heart Classification greater than&#xD;
             grade II; ischemia)&#xD;
&#xD;
          7. Peripheral vascular disease&#xD;
&#xD;
          8. History of claudication&#xD;
&#xD;
          9. Pulmonary disease&#xD;
&#xD;
         10. History of systemic or pulmonary embolus&#xD;
&#xD;
         11. Uncontrolled blood pressure (systolic BP&gt;170, diastolic BP&gt;95 mmHg)&#xD;
&#xD;
         12. Impaired renal function (creatinine &gt;1.5 mg/dl)&#xD;
&#xD;
         13. Anemia (hematocrit &lt;33)&#xD;
&#xD;
         14. Untreated thyroid disease (abnormal TSH)&#xD;
&#xD;
         15. A recent history (&lt;12 months) of GI bleed&#xD;
&#xD;
         16. Diabetes mellitus or other untreated endocrine or metabolic disease&#xD;
&#xD;
         17. Electrolyte abnormalities&#xD;
&#xD;
         18. Any history of stroke, hypo- or hyper-coagulation disorders&#xD;
&#xD;
         19. Employment requiring long (&gt;1 h) uninterrupted period of standing&#xD;
&#xD;
         20. Inability to meet study travel requirements (e.g. manual geared car)&#xD;
&#xD;
         21. Recent history of balance issues or falls.&#xD;
&#xD;
         22. Recent (3 years) treated cancer other than basal cell carcinoma&#xD;
&#xD;
         23. Systemic steroids, anabolic steroids, growth hormone or immunosuppressant use within&#xD;
             12 months&#xD;
&#xD;
         24. Recent (6 months) adherence to a weight-loss or weight-gain diet&#xD;
&#xD;
         25. Weight change of 5% or more in previous 6 months&#xD;
&#xD;
         26. Body mass index &gt;30 or excess body fat that compromises muscle biopsy collection&#xD;
&#xD;
         27. Body mass index &lt;20 or recent history (&lt;12 month) of disordered eating&#xD;
&#xD;
         28. Acute infectious disease or chronic infection&#xD;
&#xD;
         29. Alcohol or drug abuse&#xD;
&#xD;
         30. Any other condition or event considered exclusionary by study physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blake Rasmussen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Lantz, PhD</last_name>
    <phone>281-886-3018</phone>
    <email>ejlantz@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Blake Rasmussen, PhD</last_name>
    <email>blrasmus@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Lantz, PhD</last_name>
      <email>ejlantz@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>Blake Rasmussen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

